Compare · AKYA vs RVTY
AKYA vs RVTY
Side-by-side comparison of Akoya BioSciences Inc. (AKYA) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKYA and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $17.26B, about 44.4x AKYA ($388.8M).
- RVTY has hit the wire 5 times in the past 4 weeks while AKYA has been quiet.
- RVTY has more recent analyst coverage (23 ratings vs 13 for AKYA).
- Company
- Akoya BioSciences Inc.
- Revvity Inc.
- Price
- -
- -
- Market cap
- $388.8M
- $17.26B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 5
- Recent ratings
- 13
- 23
Akoya BioSciences Inc.
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. The company offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. It provides two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational, and clinical research. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Latest AKYA
- SEC Form 15-12G filed by Akoya BioSciences Inc.
- SEC Form EFFECT filed by Akoya BioSciences Inc.
- Director Mendel Scott disposed of 28,500 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Ramachandran Niro Ph.D acquired 62,566 shares, covered exercise/tax liability with 42,148 shares and disposed of 282,555 shares, closing all direct ownership in the company (SEC Form 4)
- President and CEO Mckelligon Brian disposed of 947,688 shares, acquired 724,428 shares and covered exercise/tax liability with 196,866 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Legal Officer Kamocsay Jennifer disposed of 179,272 shares, closing all direct ownership in the company (SEC Form 4)
- CFO Ek John Frederick disposed of 268,202 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Clinical Officer Bamford Pascal disposed of 205,738 shares, closing all direct ownership in the company (SEC Form 4)
- Director Winkler Matthew disposed of 984,513 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Shepler Robert G
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery